Literature DB >> 24142420

Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.

Chad Heatwole1, Rita Bode, Nicholas Johnson, Jeanne Dekdebrun, Nuran Dilek, Mark Heatwole, James E Hilbert, Elizabeth Luebbe, William Martens, Michael P Mcdermott, Nan Rothrock, Charles Thornton, Barbara G Vickrey, David Victorson, Richard Moxley.   

Abstract

INTRODUCTION: In preparation for clinical trials we examine the validity, reliability, and patient understanding of the Myotonic Dystrophy Health Index (MDHI).
METHODS: Initially we partnered with 278 myotonic dystrophy type-1 (DM1) patients and identified the most relevant questions for the MDHI. Next, we used factor analysis, patient interviews, and test-retest reliability assessments to refine and evaluate the instrument. Lastly, we determined the capability of the MDHI to differentiate between known groups of DM1 participants.
RESULTS: Questions in the final MDHI represent 17 areas of DM1 health. The internal consistency was acceptable in all subscales. The MDHI had a high test-retest reliability (ICC = 0.95) and differentiated between DM1 patient groups with different disease severities.
CONCLUSIONS: Initial evaluation of the MDHI provides evidence that it is valid and reliable as an outcome measure for assessing patient-reported health. These results suggest that important aspects of DM1 health may be measured effectively using the MDHI.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  muscle disease; myotonic dystrophy type-1; patient-relevant; patient-reported outcome measure; therapeutic trial, quality of life

Mesh:

Year:  2014        PMID: 24142420      PMCID: PMC5551891          DOI: 10.1002/mus.24097

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  22 in total

Review 1.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation.

Authors:  R A Deyo; P Diehr; D L Patrick
Journal:  Control Clin Trials       Date:  1991-08

3.  Challenges in drug development for muscle disease: a stakeholders' meeting.

Authors:  Jerry R Mendell; Cristina Csimma; Craig M McDonald; Diana M Escolar; Scott Janis; John D Porter; Sharon E Hesterlee; R Rodney Howell
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

4.  Criteria for establishing the validity of genetic recombination in myotonic dystrophy.

Authors:  R C Griggs; D S Wood
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

5.  If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  James E Hilbert; John T Kissel; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Donald B Sanders; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  Contemp Clin Trials       Date:  2011-11-26       Impact factor: 2.226

6.  Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Authors:  Chad Heatwole; Rita Bode; Nicholas Johnson; Christine Quinn; William Martens; Michael P McDermott; Nan Rothrock; Charles Thornton; Barbara Vickrey; David Victorson; Richard Moxley
Journal:  Neurology       Date:  2012-07-11       Impact factor: 9.910

7.  Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

Authors:  J Mathieu; H Boivin; D Meunier; M Gaudreault; P Bégin
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

8.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene.

Authors:  M Mahadevan; C Tsilfidis; L Sabourin; G Shutler; C Amemiya; G Jansen; C Neville; M Narang; J Barceló; K O'Hoy
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

9.  Patient Registries and Trial Readiness in Myotonic Dystrophy--TREAT-NMD/Marigold International Workshop Report.

Authors:  Rachel Thompson; Benedikt Schoser; Darren G Monckton; Karla Blonsky; Hanns Lochmüller
Journal:  Neuromuscul Disord       Date:  2009-10-20       Impact factor: 4.296

10.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

View more
  17 in total

1.  Measuring quality of life in muscular dystrophy.

Authors:  Carla M Bann; Richard T Abresch; Barbara Biesecker; Kristin Caspers Conway; Chad Heatwole; Holly Peay; Peter Scal; Jonathan Strober; Karen Uzark; Jodi Wolff; Marjorie Margolis; Angela Blackwell; Natalie Street; Angela Montesanti; Julie Bolen
Journal:  Neurology       Date:  2015-02-06       Impact factor: 9.910

2.  Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Authors:  Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

3.  Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.

Authors:  Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley
Journal:  J Neurol       Date:  2016-10-12       Impact factor: 4.849

4.  Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer-assisted evaluation.

Authors:  Gayle K Deutsch; Katharine A Hagerman; Jacinda Sampson; Gersham Dent; Jeanne Dekdebrun; Dana M Parker; Charles A Thornton; Chad R Heatwole; Sub H Subramony; Ami K Mankodi; Tetsuo Ashizawa; Jeffrey M Statland; W David Arnold; Richard T Moxley; John W Day
Journal:  Muscle Nerve       Date:  2022-02-28       Impact factor: 3.852

5.  Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Chad Heatwole; Elizabeth Luebbe; Spencer Rosero; Katy Eichinger; William Martens; James Hilbert; Jeanne Dekdebrun; Nuran Dilek; Christine Zizzi; Nicholas Johnson; Araya Puwanant; Rabi Tawil; Giovanni Schifitto; Christopher A Beck; J Franklin Richeson; Wojciech Zareba; Charles Thornton; Michael P McDermott; Richard Moxley
Journal:  Neurology       Date:  2020-10-12       Impact factor: 9.910

6.  The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.

Authors:  Nicholas E Johnson; Chad Heatwole; Peter Creigh; Michael P McDermott; Nuran Dilek; Man Hung; Jerry Bounsanga; Wan Tang; Michael E Shy; David N Herrmann
Journal:  Ann Neurol       Date:  2018-08-29       Impact factor: 10.422

7.  Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1.

Authors:  Lydia Sharp; Diana C Cox; Thomas A Cooper
Journal:  Muscle Nerve       Date:  2019-10-23       Impact factor: 3.217

8.  The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study.

Authors:  Nicholas E Johnson; Man Hung; Eriko Nasser; Katharine A Hagerman; Wei Chen; Emma Ciafaloni; Chad R Heatwole
Journal:  J Neuromuscul Dis       Date:  2015-10-07

9.  Patient-identified impact of symptoms in spinal and bulbar muscular atrophy.

Authors:  Robert D Guber; Angela D Kokkinis; Alice B Schindler; Roxanna M Bendixen; Chad R Heatwole; Kenneth H Fischbeck; Christopher Grunseich
Journal:  Muscle Nerve       Date:  2017-09-25       Impact factor: 3.217

10.  Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA).

Authors:  Giovanni DiPaolo; Cecilia Jimenez-Moreno; Nikoletta Nikolenko; Antonio Atalaia; Darren G Monckton; Michela Guglieri; Hanns Lochmüller
Journal:  J Neurol       Date:  2017-02-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.